Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
February 26 2021 - 8:00AM
Business Wire
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome
therapeutics company, today announced that management will
participate in two upcoming investor conferences:
- Cowen 41st Annual Health Care Conference on Tuesday,
March 2, 2021. Management will participate in a Microbiome panel
discussion as well as 1x1 meetings.
- Chardan 3rd Annual Microbiome Medicines Summit on
Monday, March 8, 2021. Management will present a corporate overview
at 2:30 p.m. ET and participate in 1x1 meetings.
An audio webcast of the Chardan Summit presentation will be
available under the “Investors and Media” section of Seres’
website. A replay of the presentation will become available
approximately one hour after the event and will be archived for 21
days.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of
multifunctional bacterial consortia that are designed to
functionally interact with host cells and tissues to treat disease.
Seres’ SER-109 program achieved the first-ever positive pivotal
clinical results for a targeted microbiome drug candidate and has
obtained Breakthrough Therapy and Orphan Drug designations from the
FDA. The SER-109 program is being advanced for the treatment of
recurrent C. difficile infection and has potential to become a
first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287
program has obtained Fast Track and Orphan Drug designations from
the FDA and is being evaluated in a Phase 2b study in patients with
active mild-to-moderate ulcerative colitis. Seres is evaluating
SER-401 in a Phase 1b study in patients with metastatic melanoma,
SER-301 in a Phase 1b study in patients with ulcerative colitis,
and SER-155 to prevent mortality due to gastrointestinal
infections, bacteremia and graft versus host disease. For more
information, please visit www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210226005085/en/
PR Contact Kristin Ainsworth
kainsworth@serestherapeutics.com
IR Contact Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024